MX2020011500A - Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas. - Google Patents

Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas.

Info

Publication number
MX2020011500A
MX2020011500A MX2020011500A MX2020011500A MX2020011500A MX 2020011500 A MX2020011500 A MX 2020011500A MX 2020011500 A MX2020011500 A MX 2020011500A MX 2020011500 A MX2020011500 A MX 2020011500A MX 2020011500 A MX2020011500 A MX 2020011500A
Authority
MX
Mexico
Prior art keywords
activity
cancer cells
small molecules
sub
cells growth
Prior art date
Application number
MX2020011500A
Other languages
English (en)
Inventor
Amnon Peled
Michal Abraham
Orly Eizenberg
Original Assignee
Alonbio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alonbio Ltd filed Critical Alonbio Ltd
Publication of MX2020011500A publication Critical patent/MX2020011500A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En el presente documento se proporcionan compuestos capaces de o que se pueden usar en la inducción de muerte de células cancerosas y/o la modulación de una actividad biológica de una quimiocina, por ejemplo, migración celular y/o el tratamiento de enfermedades y trastornos asociados a una actividad biológica de una quimiocina y/o migración celular y/o la inhibición de una cinasa y/o en el tratamiento de una enfermedad o un trastorno asociados a una actividad de una cinasa, tal como cáncer y enfermedades y trastornos inflamatorios. Los compuestos se representan de forma colectiva por las fórmulas Ia o Ib: (ver Fórmulas) en las que A, B D, E, G y R1-R5 R5 son como se ha definido en la memoria descriptiva.
MX2020011500A 2015-12-17 2016-12-15 Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas. MX2020011500A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562268586P 2015-12-17 2015-12-17
PCT/IL2016/051347 WO2017103932A1 (en) 2015-12-17 2016-12-15 Small molecules for inhibiting chemokine activity, a kinase activity and/or cancer cells growth

Publications (1)

Publication Number Publication Date
MX2020011500A true MX2020011500A (es) 2020-12-07

Family

ID=59056164

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020011500A MX2020011500A (es) 2015-12-17 2016-12-15 Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas.
MX2018007361A MX2018007361A (es) 2015-12-17 2016-12-15 Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018007361A MX2018007361A (es) 2015-12-17 2016-12-15 Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas.

Country Status (12)

Country Link
US (2) US11129824B2 (es)
EP (2) EP3741432B1 (es)
JP (1) JP6941611B2 (es)
KR (1) KR20180100135A (es)
CN (1) CN108699000B (es)
AU (2) AU2016371466B2 (es)
CA (1) CA3008107C (es)
DK (1) DK3390364T3 (es)
ES (2) ES2818531T3 (es)
IL (1) IL260081B (es)
MX (2) MX2020011500A (es)
WO (1) WO2017103932A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10646465B2 (en) 2015-12-17 2020-05-12 Biokine Therapeutics Ltd. Small molecules against cancer
EP3741432B1 (en) 2015-12-17 2023-05-10 AlonBio Ltd. Quinolin-2,4-one derivatives for inhibiting chemokine activity
IL307561A (en) * 2019-05-15 2023-12-01 Alonbio Ltd Compounds to treat cancer, to inhibit chemokines and/or to kill cells
JP2020193249A (ja) 2019-05-27 2020-12-03 信越化学工業株式会社 量子ドット、量子ドット組成物、波長変換材料、波長変換フィルム、バックライトユニット及び画像表示装置
WO2023244619A2 (en) * 2022-06-13 2023-12-21 Mayo Foundation For Medical Education And Research Flavonoid compounds and methods and materials for using flavonoid compounds to treat fibrotic conditions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
FR2682107B1 (fr) * 1991-10-03 1995-04-21 Orstom Inst Fs Rech Scient Quinoleines 2-substituees pour le traitement des leishmanioses.
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
MXPA00011773A (es) 1998-05-28 2002-06-04 Parker Hughes Inst Quinazolinas para tratar tumores en el cerebro.
FR2781218B1 (fr) 1998-07-15 2001-09-07 Lafon Labor Compositions pharmaceutiques comprenant des 2-quinolones
DE69924500T2 (de) 1998-08-21 2006-02-09 Parker Hughes Institute, St. Paul Chinazolinderivate
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
ATE339406T1 (de) 1999-09-23 2006-10-15 Astrazeneca Ab Chinazoline verbindungen als heilmittel
CA2398163C (en) * 2000-01-24 2011-02-22 Kinacia Pty Ltd. Therapeutic morpholino-substituted compounds
GB0028702D0 (en) 2000-11-24 2001-01-10 Novartis Ag Organic compounds
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
WO2005108431A1 (en) 2004-05-04 2005-11-17 University Of Kentucky Research Foundation Methods and compositions for the treatment of ocular neovascularization
WO2007052173A2 (en) 2005-02-23 2007-05-10 Endocube S.A.S. Activity of thap-family chemokine-binding domains
WO2007094005A2 (en) 2006-02-17 2007-08-23 Rappaport Family Institute For Research In The Medical Sciences Molecules and methods of using same for treating ccr5/ccr5 ligands associated diseases
WO2008115870A2 (en) 2007-03-16 2008-09-25 Mount Sinai School Of Medicine Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction
CN101202347A (zh) 2007-11-22 2008-06-18 山东神工海特电子科技有限公司 具有金属骨架正极的1.5v锂二硫化铁扣式电池
MX359575B (es) 2009-06-12 2018-10-03 Abivax Compuestos utiles para tratar sida.
EP2443137B1 (en) 2009-06-15 2015-05-20 Biokine Therapeutics Ltd. Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer
CN103517896B (zh) * 2011-03-07 2016-09-21 葛兰素史密斯克莱有限责任公司 喹啉酮衍生物
US20170226157A1 (en) 2014-12-09 2017-08-10 Biokine Therapeutics Ltd. Compositions and methods for the treatment of ocular diseases
EP3741432B1 (en) 2015-12-17 2023-05-10 AlonBio Ltd. Quinolin-2,4-one derivatives for inhibiting chemokine activity
US10646465B2 (en) 2015-12-17 2020-05-12 Biokine Therapeutics Ltd. Small molecules against cancer
IL307561A (en) 2019-05-15 2023-12-01 Alonbio Ltd Compounds to treat cancer, to inhibit chemokines and/or to kill cells

Also Published As

Publication number Publication date
ES2818531T3 (es) 2021-04-13
WO2017103932A9 (en) 2017-08-24
CA3008107C (en) 2023-06-27
AU2016371466B2 (en) 2020-04-09
AU2016371466A1 (en) 2018-07-19
EP3390364A1 (en) 2018-10-24
CA3008107A1 (en) 2017-06-22
MX2018007361A (es) 2019-05-16
EP3741432A1 (en) 2020-11-25
WO2017103932A1 (en) 2017-06-22
BR112018012306A2 (pt) 2018-12-04
CN108699000A (zh) 2018-10-23
JP6941611B2 (ja) 2021-09-29
IL260081B (en) 2021-09-30
IL260081A (en) 2018-07-31
ES2951385T3 (es) 2023-10-20
RU2018125293A (ru) 2020-01-17
JP2019502699A (ja) 2019-01-31
EP3390364B1 (en) 2020-07-15
DK3390364T3 (da) 2020-10-12
AU2020204524B9 (en) 2022-02-03
US20220008407A1 (en) 2022-01-13
US20190336492A1 (en) 2019-11-07
CN108699000B (zh) 2021-09-21
AU2020204524B2 (en) 2022-01-20
KR20180100135A (ko) 2018-09-07
US11129824B2 (en) 2021-09-28
AU2020204524A1 (en) 2020-07-30
EP3741432B1 (en) 2023-05-10
EP3390364A4 (en) 2018-10-24
RU2018125293A3 (es) 2020-04-06

Similar Documents

Publication Publication Date Title
MX2020011500A (es) Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas.
WO2019108733A3 (en) Cd47 antibodies and uses thereof for treating cancer
BR112018073861A2 (pt) métodos de terapia de genes para doenças e condições relacionadas com a idade
MX2017004128A (es) Derivados de diarilurea como inhibidores de quinasa p38.
ZA201707869B (en) Anti-ntb-a antibodies and related compositions and methods
PH12015502610A1 (en) Compounds for kinase modulation, and indications therefor
CL2015002194A1 (es) Inhbidores de erk y sus usos
CU20150119A7 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
EA201791624A1 (ru) СОЕДИНЕНИЯ ДЛЯ УЛУЧШЕНИЯ СПЛАЙСИНГА мРНК
MX2015002044A (es) Pirazolil-ureas como inhibidores de quinasa.
CL2010001538A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular.
NZ711896A (en) Compounds and methods for kinase modulation, and indications therefor
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
MX363950B (es) Derivados de urea utiles como inhibidores de quinasa.
MA52542A (fr) Thérapie cellulaire adoptive
MX2020005640A (es) Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama.
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
BR112018012913A2 (pt) tratamento in situ de sementes em sulco
NZ740817A (en) Pcna inhibitors
EA201001266A1 (ru) Эффективные противоопухолевые парамиксовирусы
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
MX2021014008A (es) Moléculas pequeñas para tratar el cáncer, inhibir la actividad de quimiocinas y/o inducir la muerte celular.
AR085105A1 (es) Dosificacion para tratamiento con anticuerpos anti-dominio 7 de tipo de factor de crecimiento epidermico (anti-egfl7)
MX2017006491A (es) Composiciones y métodos para la modulación de la actividad at2r.
BR112018011196A2 (pt) uso de pirimido-pirimidazinonas para tratar o câncer